KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $7.3 billion.

  • Eli Lilly's Cash & Equivalents rose 12239.9% to $7.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.3 billion, marking a year-over-year increase of 12239.9%. This contributed to the annual value of $7.3 billion for FY2025, which is 12239.9% up from last year.
  • According to the latest figures from Q4 2025, Eli Lilly's Cash & Equivalents is $7.3 billion, which was up 12239.9% from $9.8 billion recorded in Q3 2025.
  • Eli Lilly's 5-year Cash & Equivalents high stood at $9.8 billion for Q3 2025, and its period low was $2.1 billion during Q4 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $3.2 billion (2021), whereas its average is $3.5 billion.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 4586.88% in 2022, then surged by 19064.71% in 2025.
  • Over the past 5 years, Eli Lilly's Cash & Equivalents (Quarter) stood at $3.8 billion in 2021, then crashed by 45.87% to $2.1 billion in 2022, then soared by 36.36% to $2.8 billion in 2023, then increased by 15.94% to $3.3 billion in 2024, then surged by 122.4% to $7.3 billion in 2025.
  • Its Cash & Equivalents was $7.3 billion in Q4 2025, compared to $9.8 billion in Q3 2025 and $3.4 billion in Q2 2025.